Related Experiment Video
Updated: May 13, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Clinical Trial Protocol for ProBio-mHSPC: A ctDNA-driven De-escalation and Intensification Platform Trial for
Bram De Laere1, Alessio Crippa2, Andrea Discacciati2
1Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Human Structure and Repair Ghent University, Ghent, Belgium.
None:
Prostate Biomarkers trial in metastatic hormone-sensitive prostate cancer (mHSPC) tests whether circulating tumor deoxyribonucleic acid (ctDNA) can personalize first-line treatment for mHSPC by safely de-escalating therapy in patients with undetectable ctDNA and by intensifying biomarker-matched treatment in ctDNA-detectable disease, aiming to preserve outcomes while reducing toxicity and improving quality of life.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
07:21Automated Sample Preparation for the Multiplexed Analysis of Single-Cell Histone Post-Translational Modifications (sc-hPTM2)
Published on: December 19, 2025